Simultaneous mRNA COVID-19 and IIV4 Vaccination Study

Summary

This study is a prospective, randomized clinical trial. During this study, participants will be randomly assigned to receive quadrivalent inactivated influenza vaccine (IIV4) and mRNA COVID-19 vaccine either simultaneously or sequentially, 7-14 days apart. Persons in the simultaneous group will receive mRNA COVID-19 and IIV4 at Visit 1 (Day 1) and a saline placebo injection at Visit 2. Persons in the sequential group will receive mRNA COVID-19 vaccine and a saline placebo at Visit 1 (Day 1) and IIV4 injection at Visit 2. For participants receiving their primary dose series, a second dose of mRNA COVID-19 vaccine will be administered either 3 to 8 weeks or 4 to 8 weeks following the first dose, depending upon the mRNA COVID-19 vaccine provided. For those receiving a booster dose of mRNA COVID-19 only a single mRNA COVID-19 will be received in this study. Solicited symptoms of reactogenicity and adverse events will be assessed on vaccination day and daily during the 7 days following each Vaccination Visit using either electronic or paper symptoms diaries, depending on study participant preference. Quality of life data will be collected using electronic or paper diaries on day of Vaccination Visit 1 and daily during the 7 days following the visit. Serious adverse events and adverse events of special interest will be collected throughout the duration of the study. Participants are followed through Day 121. Serum samples from participants will be collected for determination of SARS-CoV-2 seropositivity at baseline. Serum samples will be taken throughout the study to determine IIV4 and COVID-19 vaccine immunogenicity and for potential future studies.

Conditions

• Quality of Life
• Injection Site Reaction
• Adverse Drug Event
• Systemic Reaction

Interventions

BIOLOGICAL

mRNA COVID-19

ACIP-CDC recommended vaccine

BIOLOGICAL

IIV4

ACIP recommended vaccine

OTHER

Placebo (saline)

Saline Control

Sponsors & Collaborators

• Centers for Disease Control and Prevention

  collaborator FED

• Johns Hopkins University

  collaborator OTHER

• Children's Hospital Medical Center, Cincinnati

  collaborator OTHER

• Duke University

  lead OTHER

Principal Investigators

• Emmanuel B Walter, MD, MPH · Duke University

• Karen R Broder, MD · Centers for Disease Control and Prevention

• Kawsar Talaat, MD · Johns Hopkins University

• Elizabeth Schlaudecker, MD, MPH · Children's Hospital Medical Center, Cincinnati

Study Design

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

TRIPLE

Model

PARALLEL

Eligibility

Min Age

5 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2021-10-04

Primary Completion

2023-03-03

Completion

2023-06-15

FDA Drug

Yes

Countries

• United States

Study Locations